MB, Levis & Associates’s Amicus Therapeutics FOLD Stock Holding History

MB, Levis & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$5.73K	–	267
2025 Q2	$5.73K	Buy	1,000 +500	+100%	+$3.23K	﹤0.01%	213
2025 Q1	$4.08K	Hold	500	–	–	﹤0.01%	225
2024 Q4	$4.71K	Sell	500 -1,000	-67%	-$10.4K	﹤0.01%	219
2024 Q3	$16K	Hold	1,500	–	–	0.01%	171
2024 Q2	$14.9K	Hold	1,500	–	–	0.01%	170
2024 Q1	$17.6K	Hold	1,500	–	–	0.01%	161
2023 Q4	$21.3K	Hold	1,500	–	–	0.01%	151
2023 Q3	$18.2K	Hold	1,500	–	–	0.01%	163
2023 Q2	$18.8K	Hold	1,500	–	–	0.01%	161
2023 Q1	$16.6K	Hold	1,500	–	–	0.01%	168
2022 Q4	$18.3K	Buy	+1,500	New	+$16.9K	0.01%	155

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MB, Levis & Associates's FOLD Position: Q3 2025 in Review

MB, Levis & Associates sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 1,000 shares — an estimated $5.73K sold.

MB, Levis & Associates first reported a position in FOLD in Q4 2022 and held it in 11 quarters. The position peaked at $21.3K in Q4 2023. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

MB, Levis & Associates reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
MB, Levis & Associates sold 1,000 Amicus Therapeutics shares in Q3 2025, an estimated $5.73K.
MB, Levis & Associates first reported a position in Amicus Therapeutics in Q4 2022 and held it in 11 quarters.
MB, Levis & Associates's Amicus Therapeutics position peaked at $21.3K in Q4 2023.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on MB, Levis & Associates's 13F filing for Q3 2025, filed 15 Oct 2025.